1. Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4
- Author
-
Amrita, Basu, Gabriella K, Albert, Sabrina, Awshah, Jashodeep, Datta, Krithika N, Kodumudi, Corey, Gallen, Amber, Beyer, Keiran S M, Smalley, Paulo C, Rodriguez, Derek R, Duckett, Peter A, Forsyth, Aixa, Soyano, Gary K, Koski, Ricardo, Lima Barros Costa, Heather, Han, Hatem, Soliman, Marie Catherine, Lee, Pawel, Kalinski, and Brian J, Czerniecki
- Subjects
CD4-Positive T-Lymphocytes ,Mice, Inbred BALB C ,Receptor, ErbB-3 ,Histocompatibility Antigens Class II ,Epitopes, T-Lymphocyte ,Breast Neoplasms ,Dendritic Cells ,Th1 Cells ,Cancer Vaccines ,Survival Analysis ,Tumor Burden ,Mice, Inbred C57BL ,Mice ,Treatment Outcome ,Cell Line, Tumor ,Animals ,Humans ,Female ,Amino Acid Sequence - Abstract
The HER3/ERBB3 receptor is an oncogenic receptor tyrosine kinase that forms heterodimers with EGFR family members and is overexpressed in numerous cancers. HER3 overexpression associates with reduced survival and acquired resistance to targeted therapies, making it a potential therapeutic target in multiple cancer types. Here, we report on immunogenic, promiscuous MHC class II-binding HER3 peptides, which can generate HER3-specific CD4
- Published
- 2021